Drug profile · INN
cemiplimab-rwlc
LIBTAYO
cemiplimab-rwlc (LIBTAYO) is a programmed cell death protein 1 inhibitor. Associated with Regeneron UK Limited. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — cemiplimab-rwlc
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 20
- Programs
- 41
- Data quality
- 0.89
Quick answer
cemiplimab-rwlc (LIBTAYO) is a programmed cell death protein 1 inhibitor. Associated with Regeneron UK Limited. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Programmed cell death protein 1 inhibitor
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12421512
CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
granted -
US 12419963
Diels-Alder conjugation methods
granted -
US 12396952
Tuning of release kinetics in hydrogels
granted -
US 12396444
Mouse comprising a humanized TRKB locus
granted -
US 12391920
Models of tauopathy
granted -
US 12391734
PD-1 homing endonuclease variants, compositions, and methods of use
granted -
US 12377159
Steroids and protein-conjugates thereof
granted -
US 12370257
Materials and methods of treating MHC-I-opathy risk haplotypes
granted -
US 12365711
TGFβ signal convertor
granted -
US 12350374
Fabrication of protein-encapsulating microgels
granted -
US 12338199
Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
granted -
US 12325752
Immunoglobulin proteins that bind to NPR1 agonists
granted -
US 12319724
IL2 agonists and methods of use thereof
granted -
US 12297465
CBLB endonuclease variants, compositions, and methods of use
granted -
US 12297279
Compositions and methods for treating pain in subjects with rheumatoid arthritis
granted -
US 12291559
Compositions and methods for treating cancer
granted -
US 12291560
Dimerizing agent regulated immunoreceptor complexes
granted -
US 12274747
Compositions and methods for treating cytokine release syndrome
granted -
US 12264343
TCRa homing endonuclease variants
granted -
US 12258627
Kelch domain containing 7B (KLHDC7B) variants and uses thereof
granted
Frequently asked questions
What is cemiplimab-rwlc?
cemiplimab-rwlc (LIBTAYO) is a programmed cell death protein 1 inhibitor. Associated with Regeneron UK Limited. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for cemiplimab-rwlc?
LIBTAYO is a marketed brand name for cemiplimab-rwlc. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cemiplimab-rwlc?
cemiplimab-rwlc has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.